Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kelch-like protein 41 (KLHL41) is a muscle-specific, structural protein crucial for the assembly, organization, and maintenance of sarcomeres in skeletal muscle. It acts primarily as a molecular chaperone, preventing aggregation and promoting the stability of the large sarcomeric protein nebulin. KLHL41 achieves this function through poly-ubiquitination-dependent mechanisms distinct from most Kelch family proteins, which more commonly target proteins for degradation. Loss-of-function mutations in KLHL41 cause nemaline myopathy, a severe congenital disorder characterized by abnormal muscle structure, sarcomere disorganization, and early-onset muscle weakness or perinatal lethality[1][2][3][4][5][6]. KLHL41 also interacts with other sarcomeric proteins, including NRAP and filamin-C, but its stabilizing effect is predominantly on nebulin. It is not currently considered a direct therapeutic target, drug receptor, or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch-like protein 41 (KLHL41).